Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw some unusual options trading activity on Monday. Stock investors purchased 9,373 call options on the stock. This is an increase of approximately 2,291% compared to the typical daily volume of 392 call options.
Aerovate Therapeutics Trading Up 278.4 %
Shares of NASDAQ AVTE traded up $7.46 during midday trading on Thursday, reaching $10.14. The company's stock had a trading volume of 185,426 shares, compared to its average volume of 17,692. The stock has a 50 day simple moving average of $2.70 and a 200-day simple moving average of $2.59. Aerovate Therapeutics has a fifty-two week low of $43.75 and a fifty-two week high of $884.98. The stock has a market capitalization of $293.91 million, a price-to-earnings ratio of -3.39 and a beta of 0.95.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.21. As a group, equities analysts anticipate that Aerovate Therapeutics will post -2.64 EPS for the current year.
Aerovate Therapeutics Dividend Announcement
The company also recently announced a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were paid a $2.40 dividend. The ex-dividend date was Tuesday, April 29th.
Hedge Funds Weigh In On Aerovate Therapeutics
A number of large investors have recently made changes to their positions in the company. Deltec Asset Management LLC grew its stake in Aerovate Therapeutics by 86.4% during the first quarter. Deltec Asset Management LLC now owns 361,804 shares of the company's stock worth $908,000 after buying an additional 167,680 shares in the last quarter. Rhumbline Advisers raised its stake in Aerovate Therapeutics by 67.3% during the first quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after acquiring an additional 9,154 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Aerovate Therapeutics in the fourth quarter worth about $1,590,000. GTS Securities LLC acquired a new position in shares of Aerovate Therapeutics in the fourth quarter worth approximately $27,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Aerovate Therapeutics during the fourth quarter valued at about $52,000.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
